British HIV Association guidelines for HIV-associated malignancies 2014

HIV Medicine

Volumn 15, Issue S2, 2014, Pages 1-92

  Bower, Mark ^a   Palfreeman, A ^b   Alfa Wali, Maryam ^c   Bunker, Chris ^c   Burns, Fiona ^d   Churchill, Duncan ^e   Collins, Simon ^f   Cwynarski, Kate ^g   Edwards, Simon ^h   Fields, Paul ⁱ   Fife, Kate ^j   Gallop Evans, Eve ^k   Kassam, Shireen ^l   Kulasegaram, Ranjababu ⁱ   Lacey, Charles ^m   Marcus, Robert ^l   Montoto, Sylvia ⁿ   Nelson, Mark ^a,o   Newsom Davis, Tom ^a   Orkin, Chloe ^p   Shaw, Kate ^c   Tenant Flowers, Melinda ^q   Webb, Andrew ^r   Westwell, Sarah ^r   Williams, Matt ^f   more..

^a CHELSEA AND WESTMINSTER HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e Worthing Hospital   (United Kingdom)

^f UK COMMUNITY ADVISORY BOARD   (United Kingdom)

^g ROYAL FREE HOSPITAL   (United Kingdom)

^h CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

ⁱ GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^j PETERBOROUGH CITY HOSPITAL   (United Kingdom)

^k VELINDRE CANCER CENTRE   (United Kingdom)

^l KING S COLLEGE HOSPITAL   (United Kingdom)

^m UNIVERSITY OF YORK   (United Kingdom)

ⁿ ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^o IMPERIAL COLLEGE LONDON   (United Kingdom)

^p BARTS HEALTH NHS TRUST   (United Kingdom)

^q KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^r ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CANCER STAGING; COMPLICATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN; IMMUNOTHERAPY; LYMPHOMA, AIDS-RELATED; MALE; PATIENT REFERRAL; PRACTICE GUIDELINE; PROGNOSIS; SARCOMA, KAPOSI; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOTHERAPY; LYMPHOMA, AIDS-RELATED; MALE; NEOPLASM STAGING; PROGNOSIS; REFERRAL AND CONSULTATION; SARCOMA, KAPOSI; UTERINE CERVICAL NEOPLASMS;

EID: 84893959067     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12136     Document Type: Article

References (73)

1. Powles T, Imami N, Nelson M et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS 2002; 16: 531-536.
2. Esdaile B, Davis M, Portsmouth S et al. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma. AIDS 2002; 16: 2344-2347.
3. Alfa-Wali M, Allen-Mersh T, Antoniou A et al. Chemoradiotherapy for anal cancer in HIV patients causes prolonged CD4 cell count suppression. Ann Oncol 2012; 23: 141-147.
4. Moore DA, Gazzard BG, Nelson MR. Central venous line infections in AIDS. J Infect 1997; 34: 35-40.
5. Dega H, Eliaszewicz M, Gisselbrecht M et al. Infections associated with totally implantable venous access devices (TIVAD) in human immunodeficiency virus-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 13: 146-154.
6. Tacconelli E, Tumbarello M, de Gaetano Donati K et al. Morbidity associated with central venous catheter-use in a cohort of 212 hospitalized subjects with HIV infection. J Hosp Infect 2000; 44: 186-192.
7. Meynard JL, Guiguet M, Arsac S et al. Frequency and risk factors of infectious complications in neutropenic patients infected with HIV. AIDS 1997; 11: 995-998.
8. Levine AM, Karim R, Mack W et al. Neutropenia in human immunodeficiency virus infection: data from the women's interagency HIV study. Arch Intern Med 2006; 166: 405-410.
9. Israel DS, Plaisance KI. Neutropenia in patients infected with human immunodeficiency virus. Clin Pharm 1991; 10: 268-279.
10. Moyle G, Sawyer W, Law M et al. Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies. Clin Ther 2004; 26: 92-97.
11. Medina I, Mills J, Leoung G et al. Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone. N Engl J Med 1990; 323: 776-782.
12. Lalezari J, Lindley J, Walmsley S et al. A safety study of oral valganciclovir maintenance treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr 2002; 30: 392-400.
13. Williams I, Churchill D, Anderson J et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012; 13(Suppl 2): 1-85.
14. Nelson M, Dockrell D, Edwards S et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIVseropositive individuals 2011. HIV Med 2011; 12(Suppl 2): 1-140.
15. Nelson MR, Shanson DC, Hawkins DA, Gazzard BG. Salmonella, Campylobacter and Shigella in HIV-seropositive patients. AIDS 1992; 6: 1495-1498.
16. DiRienzo AG, van Der Horst C, Finkelstein DM et al. Efficacy of trimethoprim-sulfamethoxazole for the prevention of bacterial infections in a randomized prophylaxis trial of patients with advanced HIV infection. AIDS Res Hum Retroviruses 2002; 18: 89-94.
17. Feikin DR, Feldman C, Schuchat A, Janoff EN. Global strategies to prevent bacterial pneumonia in adults with HIV disease. Lancet Infect Dis 2004; 4: 445-455.
18. Kohli R, Lo Y, Homel P et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43: 90-98.
19. Ribera E, Fernandez-Sola A, Juste C et al. Comparison of high and low doses of trimethoprim-sulfamethoxazole for primary prevention of toxoplasmic encephalitis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 29: 1461-1466.
20. Abgrall S, Rabaud C, Costagliola D. Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era. Clin Infect Dis 2001; 33: 1747-1755.
21. Havlir DV, Dube MP, Sattler FR et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med 1996; 335: 392-398.
22. Pierce M, Crampton S, Henry D et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med 1996; 335: 384-391.
23. Cohn DL. Prevention strategies for Mycobacterium aviumintracellulare complex (MAC) infection. A review of recent studies in patients with AIDS. Drugs 1997; 54: 8-15; discussion 28-19.
24. Benson CA, Williams PL, Cohn DL et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: a randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis 2000; 181: 1289-1297.
25. Robenshtok E, Gafter-Gvili A, Goldberg E et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007; 25: 5471-5489.
26. Annaloro C, Oriana A, Tagliaferri E et al. Efficacy of different prophylactic antifungal regimens in bone marrow transplantation. Haematologica 1995; 80: 512-517.
27. Huijgens PC, Simoons-Smit AM, van Loenen AC et al. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology. J Clin Pathol 1999; 52:376-380.
28. Morgenstern GR, Prentice AG, Prentice HG et al. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. UK Multicentre Antifungal Prophylaxis Study Group. Br J Haematol 1999; 105: 901-911.
29. Winston DJ, Maziarz RT, Chandrasekar PH et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med 2003; 138: 70-713.
30. Marr KA, Crippa F, Leisenring W et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527-1533.
31. Oren I, Rowe JM, Sprecher H et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 127-134.
32. Glasmacher A, Cornely O, Ullmann AJ et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother 2006; 57: 317-325.
33. Moriyama B, Henning SA, Leung J et al. Adverse interactions between antifungal azoles and vincristine: review and analysis of cases. Mycoses 2012; 55: 290-297.
34. Cornely OA, Maertens J, Winston DJ et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356: 348-359.
35. Ullmann AJ, Lipton JH, Vesole DH et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007; 356: 335-347.
36. Wingard JR, Carter SL, Walsh TJ et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111-5118.
37. McCarthy KL, Playford EG, Looke DF, Whitby M. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy. Clin Infect Dis 2007; 44: e55-56.
38. Cowen EW, Nguyen JC, Miller DD et al. Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. J Am Acad Dermatol 2010; 62: 31-37.
39. Miller DD, Cowen EW, Nguyen JC et al. Melanoma associated with long-term voriconazole therapy: a new manifestation of chronic photosensitivity. Arch Dermatol 2010; 146: 300-304.
40. Kuritzkes DR, Parenti D, Ward DJ et al. Filgrastim prevents severe neutropenia and reduces infective morbidity in patients with advanced HIV infection: results of a randomized, multicenter, controlled trial. G-CSF 930101 Study Group. AIDS 1998; 12: 65-74.
41. Kuritzkes DR. Neutropenia, neutrophil dysfunction, and bacterial infection in patients with human immunodeficiency virus disease: the role of granulocyte colony-stimulating factor. Clin Infect Dis 2000; 30: 256-260.
42. Tomblyn M, Chiller T, Einsele H et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238.
43. Freifeld AG, Bow EJ, Sepkowitz KA et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: e56-93.
44. Cullen M, Steven N, Billingham L et al. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 2005; 353: 988-998.
45. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
46. Baden LR. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 2005; 353: 1052-1054.
47. Flowers CR, Seidenfeld J, Bow EJ et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 2013; 31: 794-810.
48. Saral R, Burns WH, Laskin OL et al. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305: 63-67.
49. Saral R, Ambinder RF, Burns WH et al. Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 1983; 99: 773-776.
50. Boeckh M, Kim HW, Flowers ME et al. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805.
51. Centers for Disease Control and Prevention; Infectious Disease Society of America; American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49(RR-10): 1-125 CE121-127.
52. Einsele H, Ehninger G, Hebart H et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
53. Boeckh M, Gooley TA, Myerson D et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 1996; 88: 4063-4071.
54. Beck CR, McKenzie BC, Hashim AB et al. Influenza vaccination for immunocompromised patients: systematic review and meta-analysis by etiology. J Infect Dis 2012;206: 1250-1259.
55. Geretti AM, Brook G, Cameron C et al. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795-848.
56. Konopnicki D, Mocroft A, de Wit S et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19: 593-601.
57. Lo Re V 3rd, Frank I, Gross R et al. Prevalence, risk factors, and outcomes for occult hepatitis B virus infection among HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 315-320.
58. Shire NJ, Rouster SD, Stanford SD et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 309-314.
59. Vento S, di Perri G, Luzzati R et al. Clinical reactivation of hepatitis B in anti-HBs-positive patients with AIDS. Lancet 1989; 1: 332-333.
60. Lok AS, Liang RH, Chiu EK et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 1991; 100: 182-188.
61. Maruyama T, Iino S, Koike K et al. Serology of acute exacerbation in chronic hepatitis B virus infection. Gastroenterology 1993; 105: 1141-1151.
62. Yeo W, Chan PK, Zhong S et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62:299-307.
63. Bani-Sadr F, Maillard A, Ponscarme D et al. Reactivation of HBV replication in HIV-HBV infected patients. Am J Med 2003; 114: 768-769.
64. Yeo W, Zee B, Zhong S et al. Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004; 90: 1306-1311.
65. Zhong S, Yeo W, Schroder C et al. High hepatitis B virus (HBV) DNA viral load is an important risk factor for HBV reactivation in breast cancer patients undergoing cytotoxic chemotherapy. J Viral Hepat 2004; 11: 55-59.
66. Stebbing J, Atkins M, Nelson M et al. Hepatitis B reactivation during combination chemotherapy for AIDSrelated lymphoma is uncommon and does not adversely affect outcome. Blood 2004; 103: 2431-2432.
67. Leaw SJ, Yen CJ, Huang WT et al. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004; 83: 270-275.
68. Evens AM, Jovanovic BD, Su YC et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180.
69. Li YH, He YF, Jiang WQ et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006; 106: 1320-1325.
70. Loomba R, Rowley A, Wesley R et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528.
71. Brook G, Main J, Nelson M et al. British HIV Association guidelines for the management of coinfection with HIV-1 and hepatitis B or C virus 2010. HIV Med 2010; 11: 1-30.
72. Lubel JS, Angus PW. Hepatitis B reactivation in patients receiving cytotoxic chemotherapy: diagnosis and management. J Gastroenterol Hepatol 2010; 25: 864-871.
73. Davies JM, Lewis MP, Wimperis J et al. Review of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen: prepared on behalf of the British Committee for Standards in Haematology by a working party of the Haemato-Oncology task force. Br J Haematol 2011; 155: 308-317.